Physician profile
Isela Prado
NPI 1720659683
$9,272.08
in general payments reported to CMS, 2019-2025
37 companies · $3,237 in 2025
The $3,237 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $368 · 2022: $1,622 · 2023: $1,783 · 2024: $2,263 · 2025: $3,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,272 · Travel and Lodging: $9.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,272.34 |
| Travel and Lodging | $9.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,059.79 | 2022-2025 | |
| Amgen INC. | $698.81 | 2024-2025 | Repatha, Uplizna |
| Alexion Pharmaceuticals, INC. | $690.40 | 2021-2025 | Ultomiris |
| La Jolla Pharmaceutical Company | $648.25 | 2022-2025 | Giapreza, Zevtera, Xerava |
| Astrazeneca Pharmaceuticals LP | $474.49 | 2021-2025 | Andexxa, Wainua |
| Teva Pharmaceuticals USA, INC. | $463.30 | 2022-2025 | Uzedy, Austedo Xr |
| Actelion Pharmaceuticals US, INC. | $374.13 | 2023-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $370.64 | 2023-2025 | Zerbaxa, Recarbrio |
| Mallinckrodt Hospital Products INC. | $367.51 | 2024-2025 | Terlivaz |
| Axsome Therapeutics, INC. | $361.72 | 2025 | Auvelity |
| Gilead Sciences, INC. | $348.11 | 2024-2025 | Vemlidy, Epclusa, Livdelzi |
| Janssen Pharmaceuticals, INC | $287.11 | 2021-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Smith+Nephew, INC. | $275.61 | 2022-2023 | Tc-100 |
| Otsuka America Pharmaceutical, INC. | $242.29 | 2022 | |
| Becton, Dickinson and Company | $235.24 | 2024-2025 | Hemosphere |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $225.00 | 2023-2025 | Ingrezza |
| Baxter Healthcare | $220.97 | 2022-2023 | |
| Inspire Medical Systems, INC. | $132.34 | 2024 | Inspire |
| Sobi, INC | $125.00 | 2024 | |
| Kyowa Kirin, INC. | $123.16 | 2024 | |
| Fresenius Kabi USA, LLC | $122.54 | 2025 | Smoflipid |
| Pacira Pharmaceuticals Incorporated | $115.94 | 2024 | Exparel |
| Esperion Therapeutics, INC. | $115.67 | 2022 | |
| Silk Road Medical, INC. | $113.07 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Edwards Lifesciences Corporation | $111.69 | 2023 | Hemosphere |
| Avita Medical Americas, LLC | $106.34 | 2025 | Permeaderm, Cohealyx, Recell |
| Vantive US Healthcare LLC | $99.92 | 2025 | Renal - Acute |
| Glaxosmithkline, LLC. | $98.88 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $96.19 | 2025 | |
| Nxstage Medical, INC. | $90.76 | 2024 | |
| Convatec INC. | $89.18 | 2023 | |
| Vapotherm INC | $85.99 | 2023 | Vapotherm |
| Corcept Therapeutics | $83.14 | 2025 | Korlym |
| Biogen, INC. | $68.61 | 2023 | |
| Sk Life Science, INC. | $60.65 | 2022 | |
| Coloplast Corp | $53.83 | 2023 | Titan, Altis |
| Fresenius USA Marketing, INC. | $35.81 | 2024 | Nxstage System One |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isela Prado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.